51 results about "Monoamine oxidase A" patented technology

The present invention provides for the identification, isolation and uses of mammalian Monoamine Oxidase C (MAO-C), also known as renalase.

The invention discloses a monoamine oxidase from Pseudomonas sp., a coding gene, a recombinant expression vector, a recombination expression transformant, and the synthesis application of the monoamine oxidase in tetrahydroquinoline chiral amine compounds. The coding gene of the monoamine oxidase MAO5-ZMU is from Pseudomonas sp. ZMU-T01. The amino acid sequence of monoamine oxidase protein is shown in SEQID No.1, and the corresponding coding gen nucleotide sequence is shown in SEQIDNo.2; the monoamine oxidase gene can be connected with an expression carrier to construct to obtain a recombination expression plasmid; the recombination expression plasmid is converted to escherichia coli to obtain genetically engineered bacteria with monoamine oxidase activity. The genetically engineered bacteria with monoamine oxidase activity can be used for effectively catalyzing 2-methyl-1,2,3,4-tetrahydroquinoline compounds for oxidation splitting, has the characteristics of high selectivity, moderatereaction condition, environment protection and the like and can be used for the biosynthesis of the chiral tetrahydroquinoline compounds.

The invention provides a compound of formula I:

wherein A¹, A², A³, R¹, X, Y, and B have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administration of such compounds. The compounds are inhibitors of monoamine oxidase B (MAO-B) enzyme function and are useful for improving cognitive function and for treating psychiatric disorders in animals.

The invention relates to the novel use of pharmaceutical preparations in the field of pharmacy, more specifically the use of barrenwort flavones and barrenwort glycosides monomers as active components in preparing medicament for preventing and treating suppression. Pharmaceutical test shows that, the barrenwort flavones and barrenwort glycosides monomer can appreciably shorten rat's tail suspension time and forced swimming standby time, reverse the decrease of mouse sucrose consumption caused by CMS, suppress animal brain monoamines oxidation enzyme an and B, thus achieving the purpose of suppression resistance.

The invention provides a monoamine oxidase with high catalysis activity, strong enantioselectivity and good substrate survivability, and an enzyme-chemical synthesis method using the above enzyme to carry out enzyme catalyzed synthesis of (1S,2S,5R)-6,6-dimethyl-2-substituted-3-azabicyclo[3.1.0]hexane or (1S,3aR,6aS)-1-substituted-octahydrocyclopenta[c]pyrrole in order to further synthesize (1S,2S,5R)-6,6-dimethyl-2-3-azabicyclo[3.1.0]hexane-2-nitrile and its hydrolysate methyl (1S,2S,5R)-6,6-dimethyl-2-3-azabicyclo[3.1.0]hexane-2-carboxylate or further synthesize (1S,3aR,6aS)-1-octahydrocyclopenta[c]pyrrole-1nitrile The invention also provides a gene for coding the monoamine oxidase, a recombinant expression vector containing the gene, a recombinant expression transformant containing the gene, and efficient preparation methods of the vector and the transformant. The monoamine oxidase can respectively react with 3-5 and 5-5 azacyclopentamine systems with different sizes to generate corresponding imides; the imides undergo cyanide addition, so a cyanide is added to an enzyme catalysis system, and the above obtained addition product can be directly alcoholyzed in a hydrochloric acid-alcohol solution to obtain hydrochloride of amino acid methyl ester, so one-pot feeding is realized, the reaction technology is simplified, and industrial production is facilitated.

The invention relates to the application of a calcium disodium edentate and corticosteroid compound preparation in preparing medicine capable of inhibiting connective tissue growth factors and monoamine oxidase, and provides a compound preparation prepared from calcium disodium edentate and corticosteroid, which comprises the calcium disodium edentate which serves as the active component, the corticosteroid and one or more medicinal auxiliary ingredients; and the compound preparation contains the calcium disodium edentate in the weight percentage of 2 to 20 percent, glucocorticoid in the weight percentage of 0.01 to 0.1 percent, and the auxiliary ingredients which can be used for injection.

The invention relates measuring method of monoamine oxidase activity and its diagnostic kit, comprising the following steps: using the benzylamine, p-toluidine red-ª‰-azo naphthol, butyl amine, amyl amine, ª‰-phenylethylamine, tyramine and other aminated compounds as substrate, it reacted with monoamine oxidase to produce auricome, then auricome carried out coupling reaction with hydrogen peroxidase and aldehyde dehydrogenase, carrying out the reaction to turn the oxidation type coenzyme to reduction type coenzyme, detecting the ascending velocity of absorbance of main wavelength 340nm to reflect the activity of monoamine oxidase in sample by definite quantity. The method has high specificity, good accuracy. The diagnostic kit is made to double agents or tri-agent to reduce the across impact and keep the agent stability and be good for long term storage. The method can be rapidly detected by the ultra-violet/visible light analysis meter or semi-automatic/full-automatic biochemical analysis meter, so the method is easy to spread and use.

The present invention provides for the identification, isolation and uses of mammalian Monoamine Oxidase C (MAO-C), also known as renalase.

The invention relates to a monoamine oxidase diagnostic/measuring reagent (kit) which utilizes enzyme colorimetry and enzyme-linked method technologies, and meanwhile, the invention also relates to a method for measuring monoamine oxidase active concentration and compositions and components of the reagent, which belong to the technical field of medical inspection and measurement. The main components of the reagent (kit) of the invention comprise a buffer solution, coenzyme, an amine compound, sodium bicarbonate, acetyl coenzyme A, pyruvate oxidase, coenzyme A-disulfide reductase and a stabilizer; and the method comprises the following steps of: enabling a sample and the reagent to generate a series of enzymatic reactions through mixing the sample and the reagent according to a certain volume ratio, then placing the reactants under an ultraviolet/visible light analyzer and detecting the rising speed of the absorbance at a position with the dominant wavelength of 340nm to measure and calculate the active concentration magnitude of monoamine oxidase.

The invention relates to a specific two-photon fluorescent probe of monoamine oxidase A, and a preparation method and an application thereof, belonging to the field of organic fluorescent probes. Thespecific two-photon fluorescent probe comprises a compound F1 with a general formula (I) which is described in the specification; and the probe is designed by utilizing the spatial selectivity of enzyme and combining the idea of constructing a conjugated structure. The probe F1 successfully and specifically detects the activity of MAO-A in different biological samples (pure proteins, cell lysates,viable cells, mouse brain tissues and tumor tissues). The probe has high sensitivity and low cost, and is applicable to industrialization.

A highly conserved active site helix present within the P-450 superfamily of proteins is found also in monoamine oxidase (MAO) B, a major enzyme that catalyzes deamination of neuro- and vaso-active amines in the nervous system of mammals. Mutation within the conserved region of the MAO B enzyme directly reduces MAO B's activity and alters its pH profile, which allows for indirect regulation of the cellular neurotransmitters and vasoamines.

The invention provides an immobilized monoamine oxidase with firm combination and less enzyme activity loss, and an application thereof in enzyme catalysis synthesis of a (1S,2S,5R)-aza-dicyclic compound. Compared with other immobilized enzymes prepared through other methods, the immobilized enzyme prepared in the invention has the advantages of firm combination, less enzyme activity loss, simple separation, high reuse frequency, low cost of the oxidation-addition process, mild reaction conditions, environmental protection, simple operation, and easy industrial amplification, so the immobilized enzyme has very good industrial application prospect.

The invention provides phenylidene phenyl peptide compounds, a medicinal composition using the phenylidene phenyl peptide compounds as active components, and application thereof as monoamine oxidase B(MAO-B) inhibitors and application thereof to preparation of medicines for treating Parkinson's disease (PD). Monoamine oxidase B (MAO-B) has been proved to be closely related to the pathogenesis ofthe Parkinson's disease (PD) and is a classic target for research and development of the medicines for treating the Parkinson's disease (PD). The invention provides application of the phenylidene phenyl peptide compounds to preparation of the monoamine oxidase B (MAO-B) inhibitors. In-vitro kinase activity experiments prove that the phenylidene phenyl peptide compounds have a significant monoamineoxidase B (MAO-B) inhibiting effect.

The invention belongs to the technical field of biology, relates to genetic engineering, biotransformation, bioconversion and biological catalysis, and organic synthesis technology, and discloses a monoamine oxidase gene from Aspergillus albicans and application thereof in chiral amine intermediate preparation using the monoamine oxidase gene to catalyze asymmetric oxidation reaction. The monoamine oxidase AaMAO7-6 gene is 1527 bp and encodes monoamine oxidase formed by 509 amino acids. After the recombinant monoamine oxidase built by the monoamine oxidase gene is expressed, the whole-cell orenzyme is used for transforming cis-7-aza-bicyclo[3,3,0]octane to generate the key chiral intermediate of Telaprevir. The preparation method is mild in reaction conditions, high in stereoselectivity,easy to achieve industrialization and the like.

The invention belongs to the technical field of biology, relates to genetic engineering, biotransformation, bioconversion and biological catalysis, and organic synthesis technology, and discloses a monoamine oxidase gene from Aspergillus flavus and application thereof in chiral amine intermediate preparation using the monoamine oxidase gene to catalyze asymmetric oxidation reaction. The monoamineoxidase AaMAO7-6 gene is 1419 bp and encodes monoamine oxidase formed by 470 amino acids. After the recombinant monoamine oxidase built by the monoamine oxidase gene is expressed, the whole-cell or enzyme is used for transforming cis-7-aza-bicyclo[3,3,0]octane to generate the key chiral intermediate of Telaprevir. The preparation method is mild in reaction conditions, high in stereoselectivity, easy to achieve industrialization and the like.

The invention relates measuring method of monoamine oxidase activity and its diagnostic kit, comprising the following steps: using the benzylamine, p-toluidine red-ª‰-azo naphthol, butyl amine, amyl amine, ª‰-phenylethylamine, tyramine and other aminated compounds as substrate, it reacted with monoamine oxidase to produce aldehydes, then auricome carried out coupling reaction with aldehyde dehydrogenase, carrying out the reaction to turn the oxidation type coenzyme to reduction type coenzyme, detecting the ascending velocity of absorbance of main wavelength 340nm to reflect the activity of monoamine oxidase in sample by definite quantity. The method has high specificity and good accuracy. The diagnostic kit is made to double agents or tri-agent to reduce the across impact and keep the agent stability and be good for long term storage. The method can be rapidly detected by the ultra-violet/visible light analysis meter or semi-automatic/full-automatic biochemical analysis meter, so the method is easy to spread and use.

The invention provides application of Houttuynoid A for preparing a monoamine oxidase (MAO) inhibitor. Compared with the original MAO inhibitor, the inhibitory activity and the selectivity on MAO-A and MAO-B of the MAO inhibitor provided by the invention are greatly increased. The application of Houttuynoid A for preparing the MAO inhibitor is disclosed for the first time; because the skeleton type belongs to a brand new skeleton type and the MAO inhibitory activity of Houttuynoid A is strong unexpectedly, the possibility that other compounds give any inspiration does not exist; Houttuynoid A has outstanding substantive characteristics; and simultaneously, Houttuynoid A has obvious progress for treating diseases related to MAO imbalance.

The invention discloses a kit for measuring monoamine oxidase and a preparation method thereof. The kit comprises double liquid components including a reagent R1 and a reagent R2 independent of each other, wherein the reagent R1 comprises 50-150 mmol/L Tris buffer solution, 12-38 mmol/L benzylamine, 2-18 mmol/L alpha-ketoglutaric acid and 0.3-1.7 mmol/L EDTA, and the solvent is purified water; and the reagent R2 comprises 50-150 mmol/L Tris buffer solution, 0.5-2.5 mmol/L acetyl coenzyme A, 0.2-1.8 mmol/L reduced coenzyme and 0.5-3.5 KU/L glutamate dehydrogenase, and the solvent is purified water. The preparation method comprises the following steps: preparing the reagents according to the component contents; mixing a to-be-measured sample with the reagent R1 and reagent R2 for sufficient reaction; measuring the absorbance difference after reaction by a full-automatic biochemical analyzer; and calculating the concentration of monoamine oxidase in the sample according to the absorbance change. The kit and preparation method thereof disclosed by the invention have the advantages of convenient operation, high accuracy and the like.

The invention discloses an application of Lycojaponicumin C in preparation of a monoamine oxidase (MAO) inhibitor. In comparison with the existing monoamine oxidase inhibitor, the inhibitory activity and the selectivity to MAO-A and MAO-B of the monoamine oxidase inhibitor provided by the invention are improved greatly. The application of Lycojaponicumin C in preparation of the monoamine oxidase inhibitor, related to the invention, is disclosed for the first time. The skeleton type is a brand-new one, and the inhibitory activity of the inhibitor on monoamine oxidase is unexpectedly strong, so that no possibility for providing any revelation by other compounds exists. The Lycojaponicumin C has prominent substantial characteristics, meanwhile, has a remarkable progress in treatment of monoamine oxidase disorder related diseases.

The invention provides application of Norsampsone B in preparing a MAO (monoamine oxidase) inhibitor, compared with the existing MAO inhibitor, the inhibitory activity and the selectivity of MAO-A and MAO-B of the Norsampsone B are greatly improved. The application of the Norsampsone B in preparing the MAO inhibitor is disclosed for the first time, and the inhibitory activity to the MAO is high, the Norsampsone B has outstanding substantive features, and obviously has remarkable improvement for treating diseases relevant to imbalance of the MAO at the same time.

The invention relates to a monoamine oxidase diagnostic/measuring reagent (kit) which utilizes enzyme colorimetry and enzyme-linked method technologies, and meanwhile, the invention also relates to a method for measuring monoamine oxidase active concentration and compositions and components of the reagent, which belong to the technical field of medical inspection and measurement. The main components of the reagent (kit) of the invention comprise a buffer solution, coenzyme, an amine compound, sodium bicarbonate, acetyl coenzyme A, 3-formyl acetic acid, pyruvate oxidase, malonate-semialdehyde dehydrogenase and a stabilizer; and the method comprises the following steps of: enabling a sample and the reagent to generate a series of enzymatic reactions through mixing the sample and the reagent according to a certain volume ratio, then placing the reactants under an ultraviolet/visible light analyzer and detecting the rising speed of the absorbance at a position with the dominant wavelength of 340nm to measure and calculate the active concentration magnitude of monoamine oxidase.

The invention provides the application of Lathyranone A. in the preparation of monoamine oxidase (MAO) inhibitors. Compared with the existing monoamine oxidase inhibitors, its inhibitory activity and selectivity to MAO‑A and MAO‑B are greatly improved. The use of Lathyranone A. involved in the present invention in the preparation of monoamine oxidase (MAO) inhibitors is disclosed for the first time. Since the skeleton type belongs to a new skeleton type, and its inhibitory activity against monoamine oxidase is unexpectedly strong, there is no inspiration from other compounds It is possible, has outstanding substantive features, and at the same time, it is obviously a significant progress in the treatment of diseases related to monoamine oxidase disorders.